Lexicon Pharmaceuticals Inc LXRX
Find similar stocks with Morningstar Investor.
Morningstar analysts do not currently cover LXRX, but with our powerful screener, you can find stocks in the same sector, industry, or style and filter on our unbiased ratings and valuation metrics.
News
-
Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024
-
Lexicon Pharmaceuticals Receives December 20, 2024 PDUFA Goal Date for Sotagliflozin Type 1 Diabetes NDA Resubmission
-
New Published Data Highlights Potential Cost-Savings of INPEFA® (sotagliflozin) for Heart Failure
-
Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director
-
Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes
-
Data From Lexicon’s RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association
-
Analysis of INPEFA® (Sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Reviewed Journal of the American College of Cardiology
-
Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association
Trading Information
- Previous Close Price
- $2.33
- Day Range
- $2.32–2.44
- 52-Week Range
- $0.92–3.73
- Bid/Ask
- $2.36 / $2.39
- Market Cap
- $863.97 Mil
- Volume/Avg
- 3.1 Mil / 2.8 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 243.26
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 285
- Website
- https://www.lexpharma.com
Comparables
Valuation
|
Metric
|
LXRX
|
AXSM
|
HRMY
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 10.09 |
Price/Book Value | 2.04 | 28.51 | 3.74 |
Price/Sales | 243.26 | 15.99 | 3.27 |
Price/Cash Flow | — | — | 10.24 |
Price/Earnings
LXRX
AXSM
HRMY
Financial Strength
|
Metric
|
LXRX
|
AXSM
|
HRMY
|
|---|---|---|---|
Quick Ratio | 15.26 | 3.01 | 2.93 |
Current Ratio | 15.58 | 3.20 | 3.11 |
Interest Coverage | −11.46 | −55.54 | 7.56 |
Quick Ratio
LXRX
AXSM
HRMY
Profitability
|
Metric
|
LXRX
|
AXSM
|
HRMY
|
|---|---|---|---|
Return on Assets (Normalized) | −63.58% | −32.80% | 25.34% |
Return on Equity (Normalized) | −112.05% | −90.18% | 41.43% |
Return on Invested Capital (Normalized) | −66.93% | −46.12% | 30.24% |
Return on Assets
LXRX
AXSM
HRMY
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Wzbwpccz | Dnwy | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Jcrvnlgjv | Rvvjvmz | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Zyvbgqqck | Yzdhnch | $118.7 Bil | |||
| Moderna Inc
MRNA
| Qtnwrqxc | Zskf | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Hkjlqyyv | Vqcky | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Lvhzgqrcn | Zwc | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Prwqctbs | Nkfqj | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Szvvlrjl | Cjxpms | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Khxtyjq | Zngx | $15.0 Bil | |||
| Incyte Corp
INCY
| Kgkkhxsfp | Zmcnc | $13.5 Bil |